Daniel Griffin provides a clinical update on COVID-19, then we review TETRIS by Paterson NJ, modeling the effects of intervention in the US on cases and deaths, mixing PCR and serology data, and much more, including listener email.
Vincent, Kathy and Rich discuss COVID-19 research paper overload, Moderna’s mRNA vaccine Phase I results, increase of ACE2 RNA by cigarette smoke, and answer listener questions.
Vincent speaks with Peter Daszak, President of EcoHealth Alliance, a global nonprofit organization dedicated to protecting wildlife and public health from the emergence of disease.
Daniel Griffin provides a clinical update on COVID-19, then we review results showing requirement for the furin site in the SARS-CoV-2 spike for replication, US state vaccine exemptions, concerns with a rapid diagnostic test, and answers to listener questions.
Vincent, Kathy and Rich explain the Jenner Institute’s SARS-CoV-2 vaccine, the NIH decision to stop the Remdesivir study, and answer listener questions.
From the Nipah Virus International Conference in Singapore, Vincent speaks with Richard Hatchett, CEO of CEPI, about its mission to stimulate and accelerate the development of vaccines against emerging infectious diseases.
Daniel Griffin provides a weekly clinical update on COVID-19, then Michael Schmidt discusses how dentistry can be safely practiced during a pandemic, followed by answers to listener questions.
The TWiV team summarizes serology-based tests for SARS-CoV-2, lack of effect of ACE inhibitors or ARBs on COVID-19 severity, and answers listener questions.
Susan Weiss recalls some of her 40 years of research on coronaviruses, including mouse hepatitis virus, MERS-CoV, and now SARS-CoV-2.
Daniel Griffin updates the clinical situation with COVID-19 patients, followed by analysis of the remedesivir clinical trial results, and answers listener questions.